Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure Congestion is the main cause for hospital admission for worsening heart failure. Diuretics are given in the great majority of these patients in order to relieve congestion. However, adequate decongestion is not always achieved, and residual congestion at time of discharge is associated with high mortality and rehospitalization rates. 1,2 Current standard practice for the assessment of congestion is clinical examination, and the 2016 European Society of Cardiology heart failure guidelines recommend daily evaluation of signs of congestion (e.g. dyspnoea, pulmonary rales, peripheral oedema). 1 In clinical practice, frequent assessment of congestion is difficult to achieve and the assessment is often considered unreliable as interobserver variability is considerable. Therefore, there is a need for a quick, reliable, and objective way to monitor a patient's congestion status.
Adrenomedullin is a 52-amino acid ringed vasodilatory peptide hormone reflecting excessive volume overload. 3, 4 Adrenomedullin plays a role in maintaining endothelial barrier function, and disruption of the adrenomedullin system results in vascular leakage and systemic and pulmonary oedema. 4 Recently, a new immunoassay has been developed that specifically measures the biologically active adrenomedullin (bio-ADM) in plasma. 5 In emergency department patients suspected of having acute decompensated heart failure, plasma bio-ADM levels were associated with clinically important 30-day outcomes. 6 In this study, we evaluated the value of bio-ADM in reflecting and predicting a patient's congestion status.
We used data from the PROTECT trial, a randomized double-blind trial that compared rolofylline against placebo in 2033 patients with acute heart failure. 7 Signs and symptoms of congestion were assessed by the treating physician daily until day 7 (or discharge if earlier). Plasma bio-ADM levels were measured from EDTA plasma samples collected at baseline, days 2 and 7, using an immunoassay developed by Sphingotec GmbH (Hennigsdorf, Germany). 6 B-type natriuretic peptide (BNP) was serially measured using high-sensitive single molecule counting (SMC™) technology (Erenna ® Immunoassay System, Singulex Inc., Alameda, CA, USA).
A composite clinical congestion score was calculated at baseline, day 2 and day 7. 8 Baseline clinical variables and standard laboratory parameters were summarized in tertiles of bio-ADM levels ( Table 1) . Frequency (percentage) was used for categorical variables, and mean ±standard deviation (SD) or median (interquartile range) for continuous variables, depending on distribution. Trends over tertiles of bio-ADM were statistically tested with Cochran-Armitage trend test, Jonckheere-Terpstra test, and a linear regression model, depending on distribution.
Association between baseline bio-ADM levels (per SD increase), residual congestion and severity of clinical congestion at baseline was evaluated in a binary logistic regression model, dichotomizing the composite clinical congestion score to mild/moderate (score <6) and severe (score ≥6). Residual congestion was defined as a composite clinical congestion score ≥ 3 at day 7. All statistical analyses were performed using R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).
Bio-ADM levels were measured in 1562 patients, and median bio-ADM at baseline was 44.1 pg/mL (25.9-82.7). The following four findings support the hypothesis that bio-ADM is a marker of congestion:
1. Patients with higher bio-ADM levels had more signs of congestion. Table 1 shows that patients in the highest tertile of bio-ADM had greater severity of oedema, orthopnoea and elevated jugular venous pressure. 2. From 13 variables that were entered in a prediction model, bio-ADM showed the highest discriminatory value for baseline congestion [area under the curve (AUC) 0.66; 95% confidence interval (CI) 0.63-0.69; P < 0.001], which was greater than weight (AUC 0.60; 95% CI 0.57-0.63; P < 0.001) or BNP (AUC 0.55; 95% CI 0.52-0.58; P = 0.001).
The association between bio-ADM and severe clinical congestion at baseline remained significant [odds ratio (OR) 1.44, 95% CI 1.25-1.65; P < 0.001] after adjustment for a multivariable model including six independent predictors of severity of clinical congestion at baseline (i.e. body mass index, serum albumin, total cholesterol, BNP, history of atrial fibrillation, and past heart failure hospitalization). 3. Baseline bio-ADM levels were significant predictors of the presence of residual congestion by day 7 (OR 1.87, 95% CI 1.62-2.17; P < 0.001), which remained statistically significant after adjustment for baseline variables associated with congestion (OR 1.28, 95% CI 1.06-1.54; P = 0.012). Baseline bio-ADM also showed the strongest discriminatory value for the presence of significant residual congestion by day 7 (AUC 0.66; 95% CI 0.63-0.70; P < 0.001). 4. In patients with no/mild residual congestion at day 7, bio-ADM levels had decreased between baseline and day 7, whereas patients with significant residual congestion at day 7 had higher baseline bio-ADM values, and these levels remained higher up to day 7. In contrast, BNP levels decreased in all patient groups after admission, irrespective of residual congestion status by day 7 (Figure 1 ).
Our findings suggest that bio-ADM is a potential marker of congestion status both at admission and during/after hospitalization for acute heart failure. This hypothesis is further supported by the biological role of adrenomedullin. Adrenomedullin expression is stimulated by volume overload, and increased plasma adrenomedullin reflects excessive fluid volume. 4 Adrenomedullin is thought to counteract tissue fluid overload by maintaining endothelial barrier function. 3 In experimental studies, adrenomedullin inhibits actin-myosin based endothelial cell contraction and junctional disassembly, thereby preventing paracellular permeability and oedema formation. 9 Moreover, adrenomedullin knock-out mice die early from systemic congestion, and infusion of adrenomedullin in animals made them more resistant to pulmonary and systemic vascular leakage. ...................................................................................................................................................................................................................................   ...................................................................................................................................................................................................................................... 
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Research letters Figure 1 Biologically active adrenomedullin (bio-ADM) and B-type natriuretic peptide (BNP) levels over time by residual congestion status at day 7. Patients were divided into groups with no significant residual congestion (score < 3), with mild residual congestion (score ≥ 3 yet <6), and with severe residual congestion (score ≥ 6). P-values represent statistical significance of within-subject differences in bio-ADM and BNP over time, as assessed using dependent samples t-tests. Ln, natural logarithm.
This study has a number of limitations. Firstly, it is a retrospective analysis of a randomized controlled trial. Secondly, causality cannot be proven. Furthermore, congestion was diagnosed using a congestion score based on assessments of local physicians. Studying the association of bio-ADM and more objective measures of congestion, such as lung ultrasound might strengthen our findings. 10, 11 Our findings suggest that bio-ADM is a potential marker of congestion status both at admission and during/after hospitalization, and might be useful to guide decongestive therapies. More studies are warranted to further establish the value of bio-ADM in acute heart failure.
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